Karolinska Development AB: Pergamum Announces Last Visit of Last Patient in a Phase I/II Trial of a Potential New Treatment for Hard-to-Heal Wounds  
4/19/2013 11:24:23 AM

STOCKHOLM--(BUSINESS WIRE)--Regulatory News: Karolinska Development AB (STO:KDEV):

Pergamum AB announced today that the company has reached last-patient-last-visit (LPLV) in a randomized Phase I/II trial of LL-37 for the treatment of hard-to-heal venous leg ulcers. Karolinska Development AB is the majority owner of Pergamum.

Non-healing wounds are a sizable burden for the individual patient and for the health care system. Today, there are more than 15 million patients globally, and virtually no medical progress has been made over the last few decades in regard to pharmacological treatments.